Holen Sie sich die Stockscreener-App
2.20
3.77%
0.08
Schlusskurs vom Vortag:
$2.12
Offen:
$2.14
24-Stunden-Volumen:
79,013
Relative Volume:
0.30
Marktkapitalisierung:
$19.77M
Einnahmen:
$14.58M
Nettoeinkommen (Verlust:
$-12.57M
KGV:
-0.3873
EPS:
-5.68
Netto-Cashflow:
$-13.07M
1W Leistung:
-5.98%
1M Leistung:
-20.29%
6M Leistung:
+5.77%
1J Leistung:
-25.42%
1-Tages-Spanne:
$2.10
$2.23
1-Wochen-Bereich:
$2.10
$2.50
52-Wochen-Spanne:
$1.98
$7.95
Vivos Therapeutics Inc Stock (VVOS) Company Profile
Firmenname
Vivos Therapeutics Inc
Sektor
Branche
Telefon
(866)908-4867
Adresse
7921 SOUTHPARK PLAZA,, LITTLETON
Vergleichen Sie VVOS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VVOS
Vivos Therapeutics Inc
|
2.20 | 15.91M | 14.58M | -12.57M | -13.07M | -5.68 |
|
ABT
Abbott Laboratories
|
128.11 | 215.57B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.88 | 143.20B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
368.27 | 137.86B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
101.20 | 127.43B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
85.13 | 48.80B | 5.88B | 1.34B | 799.60M | 2.3489 |
Vivos Therapeutics Inc Aktie (VVOS) Neueste Nachrichten
Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges - MSN
Why Vivos Therapeutics Inc. stock remains on buy lists2025 Geopolitical Influence & High Accuracy Investment Signals - newser.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q3 2025 Earnings Call Transcript - Insider Monkey
Vivos Therapeutics Inc. (VVOS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Receives $5.44 Average Target Price from Analysts - Defense World
Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift - MSN
Published on: 2025-11-20 02:04:52 - newser.com
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth By Investing.com - Investing.com Nigeria
Vivos Therapeutics signals continued revenue acceleration amid SCN integration and SAMC expansion plans - MSN
Vivos Therapeutics Q3 2025 Earnings Call Transcript - MarketBeat
Why Vivos Therapeutics Inc. stock appeals to analystsFed Meeting & Technical Confirmation Alerts - newser.com
Earnings call transcript: Vivos Therapeutics Q3 2025 shows revenue growth - Investing.com India
What technical charts say about Vivos Therapeutics Inc. stockWeekly Gains Summary & Verified Entry Point Signals - newser.com
Vivos Therapeutics Rides Acquisition Wave To Higher Revenue - Finimize
[8-K] Vivos Therapeutics, Inc. Reports Material Event | VVOS SEC FilingForm 8-K - Stock Titan
Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025 - The Globe and Mail
Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition - MarketScreener
Vivos Therapeutics (NASDAQ: VVOS) reports 78% third quarter revenue growth - Stock Titan
[10-Q] Vivos Therapeutics, Inc. Quarterly Earnings Report | VVOS SEC FilingForm 10-Q - Stock Titan
Vivos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
Vivos Therapeutics, Inc. Plans Q3 2025 Financial Results Release and Investor Conference Call - Quiver Quantitative
Vivos Therapeutics (NASDAQ: VVOS) to Release Q3 2025 Results, Host Call Today - Stock Titan
Vivos Therapeutics (NASDAQ:VVOS) Coverage Initiated at HC Wainwright - Defense World
HC Wainwright & Co. Initiates Coverage of Vivos Therapeutics (VVOS) with Buy Recommendation - Nasdaq
Vivos Therapeutics (VVOS) Receives New Coverage From HC Wainwrig - GuruFocus
This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
HC Wainwright Initiates Vivos Therapeutics at Buy With $7 Price Target - MarketScreener
Vivos Therapeutics Delays Q3 Report Amid Acquisition - MSN
Is Vivos Therapeutics Inc. stock a safe haven asset2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
What institutional flow reveals about Vivos Therapeutics Inc.Weekly Trade Analysis & Risk Controlled Daily Trade Plans - newser.com
Can Vivos Therapeutics Inc. stock surprise with earnings upside2025 Top Gainers & AI Enhanced Trading Alerts - newser.com
How risky is Vivos Therapeutics Inc. stock now2025 Winners & Losers & Free Community Supported Trade Ideas - newser.com
Will Vivos Therapeutics Inc. continue its uptrend2025 Major Catalysts & Weekly Sector Rotation Insights - newser.com
Is Vivos Therapeutics Inc. stock undervalued vs historical averagesTrade Exit Summary & Stepwise Swing Trade Plans - newser.com
How supply chain issues affect Vivos Therapeutics Inc. stock2025 Price Targets & Free Technical Confirmation Trade Alerts - newser.com
Exit strategy if you’re trapped in Vivos Therapeutics Inc.Weekly Trade Analysis & Accurate Technical Buy Alerts - newser.com
Vivos Therapeutics files for non-timely 10-Q with US SEC - MarketScreener
[NT 10-Q] Vivos Therapeutics, Inc. SEC Filing - Stock Titan
Will Vivos Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & Weekly Breakout Watchlists - Fundação Cultural do Pará
Vivos Therapeutics, Inc. (VVOS) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Will Vivos Therapeutics Inc. see short term momentumWeekly Stock Analysis & Weekly Top Gainers Trade List - newser.com
Finanzdaten der Vivos Therapeutics Inc-Aktie (VVOS)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):